Inpharma 1455 - 18 Sep 2004

Perindopril/indapamide superior toatenolol in hypertension

First-line therapy with perindopril/indapamide issuperior to atenolol for reducing systolic BP, pulsepressure and left ventricular mass (LVM) in patients withessential hypertension, according to a multinationalgroup of researchers.

The REASON* study included 214 such patients aged18–84 years who were randomised to receive one totwo tablets of either perindopril/indapamide2/0.625 mg/day, or atenolol 50 mg/day, for 12 months.

Systolic BP reduction was significantly greater inperindopril/indapamide, compared with atenolol,recipients (reduction of 21.2 vs 15.3mm Hg), althoughboth treatments were associated with similar reductionsin diastolic BP. Pulse pressure was lowered to asignificantly greater extent in perindopril/indapamide,versus atenolol, recipients (9.1 vs 4mm Hg), whereasthe reduction in heart rate was significantly greater withatenolol (6.7 vs 2.5 beats/min).

At the end of treatment, the parameters for leftventricular internal dimension, posterior wall thicknessand interventricular septum thickness were allsignificantly reduced in perindopril/indapamide-treatedpatients, by 0.62, 0.29 and 0.22mm, respectively, whileno significant differences were observed in atenololrecipients. The LVM was decreased to a significantlygreater extent in perindopril/indapamide recipients,compared with atenolol-treated patients (reduction of13.6g vs 4.3g).* PREterax in Regression of Arterial Stiffness in a ContrOlled Double-BliNd Study

De Luca N, et al. Regression of left ventricular mass in hypertensive patientstreated with perindopril/indapamide as a first-line combination: the REASONEchocardiography Study. American Journal of Hypertension 17: 660-667, No. 8,Aug 2004 800989071

1

Inpharma 18 Sep 2004 No. 14551173-8324/10/1455-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved